Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 10/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21001877 | 0.79 | AKR1C3 (0.52) | AKR1C3APEX1TBXAS1RXRARXRB | |
| SCHEMBL21002161 | 0.79 | AKR1C3 (0.52) | AKR1C3APEX1TBXAS1RXRARXRB | |
| SCHEMBL21040574 | 0.79 | AKR1C3 (0.52) | AKR1C3APEX1TBXAS1RXRARXRB | |
| SCHEMBL641498 | 0.78 | AKR1C3 (0.45) | AKR1C3APEX1TBXAS1RXRARXRB | |
| SCHEMBL17368454 | 0.76 | AKR1C3 (0.44) | AKR1C3APEX1TBXAS1RXRARXRB | |
| SCHEMBL17368452 | 0.68 | AKR1C3 (0.53) | AKR1C3APEX1TBXAS1RXRARXRB | |
| SCHEMBL83882 | 0.67 | AKR1C3 (0.69) | AKR1C3TBXAS1 | |
| SCHEMBL3418803 | 0.67 | AKR1C3 (0.57) | AKR1C3APEX1TBXAS1 | |
| SCHEMBL83883 | 0.67 | AKR1C3 (0.69) | AKR1C3TBXAS1 | |
| SCHEMBL8746648 | 0.67 | AKR1C3 (0.57) | AKR1C3APEX1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | Technische Universität Berlin (DE) | 2019-06-04 | — | — | US | disclosed |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2015-12-31 | — | — | US | disclosed |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | MB, ALB, BCAT2 | AKR1C3 3026/4885APEX1 1664/4885TBXAS1 1875/4885 |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | MB, ALB, BCAT2 | AKR1C3 3026/4885APEX1 1664/4885TBXAS1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.